We are live on ! Find out more
CLCD

CoLucid Pharmaceuticals, Inc.
CLCD

Delisted

CLCD was delisted on the 28th of February, 2017.

Back to rankings

1 hedge funds and large institutions have $55K invested in CoLucid Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 71 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 71

99% less funds holding

Funds holding: 76 → 1 (-75)

100% less capital invested

Capital invested by funds: $503M → $55K (-$503M)

100% less funds holding in top 10

Funds holding in top 10: 6 → 0 (-6)

Holders
1
Holders Change
-75
Holders Change %
-98.68%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-100%
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
71
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
-$858K

Top Buyers

Rank Fund Capital Flow
1
FPF
FNY Partners Fund
New York
+$51.9K

Top Sellers

Rank Fund Capital Flow
1
NHAS
Novo Holdings A/S
Denmark
-$115M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$84.8M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$48M
4
Citadel Advisors
Citadel Advisors
Florida
-$25.6M
5
PA
Perceptive Advisors
New York
-$23.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
26
Atika Capital Management
New York
– -$2.49M -68,400 Closed
KCM
27
Kingdon Capital Management
New York
– -$2.2M -60,461 Closed
BCM
28
Bridgeway Capital Management
Texas
– -$2.18M -60,000 Closed
TD Asset Management
29
TD Asset Management
Ontario, Canada
– -$2.04M -55,956 Closed
Geode Capital Management
30
Geode Capital Management
Massachusetts
– -$1.96M -53,805 Closed
WMSA
31
Weiss Multi-Strategy Advisers
New York
– -$1.82M -50,000 Closed
Russell Investments Group
32
Russell Investments Group
United Kingdom
– -$1.58M -42,998 Closed
Renaissance Technologies
33
Renaissance Technologies
New York
– -$1.51M -41,600 Closed
BBA
34
Baker Bros. Advisors
New York
– -$1.1M -30,310 Closed
Allianz Asset Management
35
Allianz Asset Management
Germany
– -$1.09M -29,989 Closed
Ameriprise
36
Ameriprise
Minnesota
– -$1.08M -29,814 Closed
Bank of New York Mellon
37
Bank of New York Mellon
New York
– -$1.02M -27,930 Closed
Northern Trust
38
Northern Trust
Illinois
– -$652K -17,911 Closed
Goldman Sachs
39
Goldman Sachs
New York
– -$597K -16,404 Closed
SSA
40
Schonfeld Strategic Advisors
New York
– -$591K -16,240 Closed
PPA
41
Parametric Portfolio Associates
Washington
– -$531K -14,587 Closed
Morgan Stanley
42
Morgan Stanley
New York
– -$499K -13,723 Closed
ProShare Advisors
43
ProShare Advisors
Maryland
– -$463K -12,716 Closed
Swiss National Bank
44
Swiss National Bank
Switzerland
– -$444K -12,200 Closed
Neuberger Berman Group
45
Neuberger Berman Group
New York
– -$437K -12,000 Closed
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
– -$435K -11,939 Closed
State Street
47
State Street
Massachusetts
– -$422K -11,600 Closed
Deutsche Bank
48
Deutsche Bank
Germany
– -$395K -10,869 Closed
DTL
49
Dynamic Technology Lab
Singapore
– -$392K -10,763 Closed
SIM
50
Strategic Investment Management
Virginia
– -$323K -8,876 Closed
1
2
3

CLCD Hedge Fund Activity: Q1 2017 in Review

1 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in CoLucid Pharmaceuticals, Inc. (CLCD) for Q1 2017, worth a combined $55K — down 100% from $503M a quarter earlier.

Sellers outnumbered buyers: 71 funds closed out of CLCD and 1 opened new positions — a net loss of 70 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was FNY Partners Fund, opening a new position worth an estimated $51.9K. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $115M sold.

  • 1 institutional investor held CoLucid Pharmaceuticals, Inc. (CLCD) as of Q1 2017, down from 76 in Q4 2016.
  • Funds reported $55K of CoLucid Pharmaceuticals, Inc. stock for Q1 2017, down 100% quarter-over-quarter.
  • 1 fund opened new CoLucid Pharmaceuticals, Inc. positions in Q1 2017 and 71 closed out, a net change of -70 holders.
  • The largest CoLucid Pharmaceuticals, Inc. buyer in Q1 2017 was FNY Partners Fund, an estimated $51.9K added.
  • The largest CoLucid Pharmaceuticals, Inc. seller in Q1 2017 was Novo Holdings A/S, an estimated $115M sold.

Based on aggregated 13F filings for Q1 2017.